Radium-223, enzalutamide, and a bone-protecting agent may be a new treatment option for mCRPC patients with bone metastases, according to Silke Gillessen, MD.

Recommended treatment for men with metastatic prostate cancer could be turned on its ear by a clinical trial spanning five countries and led by Dr. Isaac Kim, professor and department chair of the ...

Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel ...

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...

STAG2 loss in Ewing sarcoma alters enhancer-promoter contacts dependent and independent of EWS::FLI1- ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment ... the incidence of skeletal-related events (SREs) in bone metastatic CRPC (mCRPC). Denosumab compared with zoledronic ...

The company will evaluate the Hepzato kit as a combination therapy with the standard of care in patients with liver-dominant ...

The dual primary end points, assessed in patients with centrally confirmed MSI-H or dMMR unresectable or metastatic colorectal cancer, were progression-free survival as determined by blinded ...

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for ...

The following is a summary of “Non-Conditional and Conditional Metastasis of Uveal Melanoma Per Millimeter-By-Millimeter in Thickness in 8034 Patients,” published in the November 2024 issue of ...

As discussed in the beginning, in some cases lung cancer can spread to other parts of the body such as the brain, liver, and ...